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Abstract
Migraine is a common and painful neurological disorder, with genetic and environmental components.
Several conditions have been shown to be comorbid with migraine, notably a cardiac malformation
affecting the interatrial septum and leading to patent foramen ovale (PFO). Mutations in the development
regulatory gene GATA-4, located on human chromosome 8p23.1-p22, have been found to be responsible
for some cases of congenital heart defects including PFO. To determine whether the GATA-4 gene is
involved in migraine, the present study performed an association analysis of a common GATA-4 variant
that results in a change of amino acid (S377G), in a large case/control population (275 unrelated
Caucasian migraineurs versus 275 control individuals). The results showed that there was no significant
association for this polymorphism between migraine and controls (x2 = 0.84, P = 0.66). Thus it appears
that the GATA-4 (S377G) mutation does not play a significant role in common migraine susceptibility.
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Abstract: Migraine is a common and painful neurological disorder, with genetic and environmental components. Several conditions have been shown to be comorbid with migraine, notably a cardiac malformation affecting the interatrial septum and leading to patent foramen ovale (PFO). Mutations in the development regulatory gene GATA-4, located on human chromosome 8p23.1-p22, have been found to be responsible for some
cases of congenital heart defects including PFO. To determine whether the GATA-4 gene is involved in migraine, the present study performed an association analysis of a common GATA-4 variant that results in a
change of amino acid (S377G), in a large case/control population (275 unrelated Caucasian migraineurs versus 275 control individuals). The results showed that there was no significant association for this polymorphism between migraine and controls ( = 0.84, P = 0.66). Thus it appears that the GATA-4 (S377G) mutation does not play a significant role in common migraine susceptibility.

Keywords: Migraine, genetic association, GATA 4 polymorphism, Heart disorder.
INTRODUCTION
Migraine is a common and debilitating neurological disease that affects a significant proportion of the population,
usually affecting 10%-12% of the Western population [1].
Characteristic manifestations of migraine include head pain,
nausea, vomiting, photophobia and often severe neurological
disturbances [2]. The most common forms of this disorder
have been classified as migraine with aura (MA) and migraine without aura (MO) [2]. One of the most important
aspects of the pathophysiology of migraine is the inherited
nature of the disorder, with twin studies showing the importance of both genetic and environmental factors [3]. Migraine is now usually viewed as a polygenic multifactorial
disease, with both environmental and genetic causative factors, and with multiple possibly interacting genes [4]. The
age of onset for this disorder also varies, but in females it has
been found that it is usually at puberty or shortly after, being
less frequent in middle life and developing three times as
often in woman as in men [5].
Several disorders have been shown to be comorbid with
migraine, including epilepsy, asthma, depression, stroke and
some congenital heart defects [6]. The cardiovascular association between migraine and ischaemic stroke is not coincidental and it could be due to a common genetic component
and to the presence of different mutations in the same gene
[7]. One heart disorder that has been associated with
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migraine is the cardiac malformation, patent foramen ovale
(PFO) [6].
Patent foramen ovale results from an incomplete anatomic fusion of the atrial septum primum and secundum,
which normally takes place shortly after birth [8]. This condition leads to a persistent connection between the right and
left atrium of the heart, by which right-to-left shunt may result [8]. Large shunts more often than small shunts are associated with migraine with aura [9, 10]. PFO is believed to
play a role in cryptogenic stroke via presumed paradoxical
embolism [11]. The right to left shunt brought about by PFO
could enhance migraine by affecting systemic levels of brain
platelet neuromediators, like 5-hydroxytriptamine (5-HT),
which is normally, inactivated by the pulmonary filter, thus
triggering a migraine attack [12, 13].
Consequently, the increased risk of stroke in patients
with MA could be explained by an increased propensity to
paradoxical embolism [8]. The prevalence of PFO in the
healthy population is approximately 20%-25%. A high
prevalence of right to left shunt has been observed in patients
with MA compared to healthy control subjects with a 41%48% PFO prevalence in migraine with aura patients [11].
Migraine has been shown to be an independent risk factor
for subsequent coronary heart disease events among women
in the Women’s Health Study (WHS) and in men in the Physician’s Health Study (PHS) [11]. Recent evidence has
shown that migraineurs who experience an aura are twice as
likely to have a PFO compared to the general population
[14]. Association between PFO and migraine has been found
to be stronger in patients with MA than in those without aura
[15]. Recent reports have emphasised an association between
PFO, MA and stroke with 25 patients (PFO was considered
2008 Bentham Open
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to play a causal role in stroke) among 74 consecutive patients with cryptogenic stroke found to have a 52% prevalence of MA [12]. The incidence of PFO in patients with
migraine is about 50% if migraine is accompanied by visual
aura, versus 20% in the general population [16].
Mutations in developmental regulatory genes have been
found to be responsible for some cases of congenital heart
defects [17]. GATA-4 is one such regulatory gene. It is part
of the GATA family of zinc finger transcription factors [18],
which play important roles in transducing nuclear events that
modulate cell lineage differentiation during development and
hypertrophy of adult cardiac myocytes [18].
To investigate the potential role of GATA-4 gene in migraine an association study of the S377G polymorphism was
conducted in a migraine case and age, sex and ethnicity
matched control population. The S377G polymorphism
(rs3729856) is located in exon 5 of GATA-4 gene and was
genotyped using a new silica bead-based technology. It is a
non-synonymous coding polymorphism with an amino acid
change (serine to glycine) and unpublished studies (R.H.,
L.G., unpublished data) have shown a reasonably high frequency of the S377G rarer allele in Caucasian populations
(Australian Caucasians (n=400, 13.9%).

case/control population (275 unrelated Caucasian migraineurs versus 275 control individuals), using forward
primer: 5’ TGT CCC CGG CAA ATG TAG ATA AAG’3
and reverse primer: 5’ CAG TCG GCC TCC CCA CAA
ACA GC ’3, resulting in a 318 base pair fragment following
PCR. The thermocycler conditions were 94˚C for 15 minutes
followed by 40 cycles at 94˚C for 30 seconds, 56˚C for 30
seconds, and 72˚C for 30 seconds. PCR was completed with
an extended incubation of 5 minutes at 72˚C. The genotyping
was undertaken by means of single nucleotide polymorphism
(SNP) genotyping, using flow cytometry developed by Genera Biosystems. This is a silica bead-based SNP genotyping
system that discriminates between alleles on the basis of
competitive hybridisation between fluorescently labelled
allele specific probes. In addition to the forward and reverse
primers a mix containing three reagents specific for the SNP
detection were used. These reagents consisted of, the AmpaSandTM beads with a covalently bound oligonucleotides
which is complementary to the ssDNA, an oligonucleotide
probe specific for one allele labelled with a yellow or green
dye and an oligonucleotide probe specific for the alternative
allele labelled with a red dye. Each reaction was analysed by
a FACSArray flow cytometer. Genotypes for all samples
were determined by MPlots© software.

MATERIALS AND METHODS

Sequencing

Subjects

The samples were sequenced using ABI Prism 377 dideoxy chain termination reaction. To confirm the results previously obtained by SNP genotyping, 5% of the population
was sequenced. The sequences produced were analysed
through the computer software CHROMAS.

This research has been approved by the Griffith University Ethics Committee for experimentation on human subjects; all participants of the study gave consent. The association population has been matched for sex, age (+/- 5 years),
and ethnicity. All subjects were of Australian Caucasian origin, interviewed by clinical neurologists and were diagnosed
for either migraine without aura (MO) or migraine with aura
(MA) according to the criteria of the International Headache
Society [2]. None of the subjects were tested for PFO or
other heart disorders. The study population comprised 275
migraineurs and 275 unrelated control individuals, with the
control group matched for sex, age (+/- 5 years), and ethnicity, to minimize potential bias from population stratification.
Genotyping
In this study we utilized standard polymerase chain reaction (PCR) analysis for the genotyping of the migraine
Table 1.

Statistics
Chi-square analysis was used to determine if the allele
frequency of the S377G polymorphism in the GATA-4 gene
were associated or not with migraine, and if the allele frequencies were significant ( = 0.05). Chi-square analysis
was also used to determine if the obtained genotype frequencies were in Hardy-Weinberg equilibrium.
Ethical approval
This research was reviewed and approved by the Griffith
University Human Research Ethics Committee (ethics proto-

Distribution of the S377G Polymorphism in Migraineurs and Controls of Original Sample (MO Migraine without Aura,
MA Migraine with Aura)
Genotypes (n %)

Alleles (allele frequency %)

Genotypes

AA

GA

GG

total (n)

A

G

total (n)

Migraine

158 (81%)

34 (18%)

2 (1%)

194

350 (90.2%)

38 (9.8%)

388

FEMALE

111 (81%)

25 (18.2%)

1 (0.8%)

137

247 (90%)

27 (10%)

274

MALE

47 (82.4%)

9 (15.8%)

1 (1.8%)

57

103 (90.4%)

11 (9.6%)

114

MA

93 (80.8%)

21 (18.3%)

1 (0.9%)

115

207 (90%)

23 (10%)

230

MO

65 (82.3%)

13 (16.5%)

1 (1.2%)

79

143 (90.5%)

15 (9.5%)

158

CONTROL

169 (84.1%)

29 (14.4%)

3 (1.5%)

201

367 (91.3%)

35 (8.7%)

402

FEMALE

122 (84.1%)

20 (13.8%)

3 (2.1%)

145

264 (91%)

26 (9%)

290

MALE

47 (83.9%)

9 (16.1%)

0 (0)

56

103 (92%)

9 (8%)

112
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col number MSC/05/05/HREC) and all subjects participating
in the study gave informed consent.

frameshift mutation affecting critical residues arginine and
histidine [21].

RESULTS

A number of studies have found a strong association between PFO and cryptogenic stroke, due to an increase of
right heart pressure therefore predisposing to paradoxical
embolism [22, 23]. A further association that has been increasingly reported is the one between migraine, particularly
migraine with aura, and PFO [24]. A number of studies have
shown an increased prevalence of PFO in young patients that
present with migraine with aura and cryptogenic stroke [8,
16]. The severity of this disorder varies according to the size
of the opening found in the heart of the patient. Family studies suggest that PFO is potentially associated with migraine
with aura particularly as a risk factor for stroke in women
[25, 26].

To determine whether the GATA-4 mutation had an important role in migraine, an association analysis of the
S377G polymorphism in a large case/control population of
migraineurs was performed. Genotypes for 194 cases and
201 controls were determined for the case/control tested
population (275/275). The genotype data can be observed in
Table 1 as well as the allele frequency for the migraine and
control populations. Statistical analysis of the S377G polymorphism revealed that there was no significant difference
( = 0.84, P = 0.66) between the migraine population and
the controls. Moreover there was no significant difference
observed in the migraine and control population with regards
to female and males for this particular association study.
Furthermore no association was found between migraine
with aura and controls ( = 0.99, P = 0.61), nor between
migraine without aura and controls ( = 0.2, P = 0.91).
Hardy Weinberg equilibrium was investigated for both migraine cases and controls. It was found that allele frequencies
did not deviate from Hardy Weinberg equilibrium in both the
case and control groups (P = 0.91; P = 0.19).

The GATA-4 gene contains a common variation that results in a S377G polymorphism missense mutation with an
alternative nucleotide of A/G, changing from the serine
amino acid to the glycine amino acid. The variant is prevalent in a number of dispersed Caucasian populations and the
allele frequency in Australian Caucasians is 13.9% (R.H. and
L.G., unpublished data). It thus could conceivably play a role
as a common contributing allele to a disorder like migraine.
This study aimed to determine the role of the S377G polymorphism in the GATA-4 gene in migraine and if there is a
significant association between patients with migraine and
this mutation. Genotypes were determined for the S377G
polymorphism but results showed no association with migraine in the case/control groups studied. Moreover there
was no significant association found between migraine with
aura and the control population and no significant difference
was observed between females with migraine versus control
females for the migraine population.

DISCUSSION
Six family members of have been identified in vertebrates to be part of the GATA family and have been subdivided in two groups: GATA-1, GATA-2, and GATA-3, which
are expressed in the hematopoetic system [19]. GATA-4,
GATA-5 and GATA-6, which are critical for differentiation
and cell-specific gene expression in different endoderm and
mesoderm, derived tissues [19]. The human GATA-4 gene is
located in chromosome 8p23.1-p22 and contains 6 exons
[20] and regulates its expression through its zinc finger [21].
It is widely expressed in the endoderm, mesoderm, heart,
gonads, liver, small intestine and pancreas [19]. Functional
studies have shown a role for the GATA-4 gene in cardiac
embryogenesis [21] and mutations in this gene have been
found to be associated with congenital heart defects such as
atrial septal defect (ASD) and patent foramen ovale (PFO)
[17].

Several studies have reported a higher prevalence of migraine in patients suffering from congenital heart disease
[24, 26, 27]. Recently, Hirth and collaborators have studied
the prevalence between congenital heart disease sufferers
with migraine [28]. They reported an increased prevalence of
migraine with aura in congenital heart disease more specifically in PFO patients (89% of these patients suffer from migraine) [28].
In addition, Tatdelide et al. has studied the prevalence of
PFO in migraine sufferers [29]. They have found percentages of PFO in migraine patients with aura, without aura and

Reamon-Buettner et al. (2005) found six mutations in the
N-finger of GATA-4 in patients with PFO. This includes a
homozygous deletion (677delC), that would lead to a
Table 2.

Chi-Squared ( 2) Analysis of all Migraine Groups Against Controls for the S377G Polymorphism
Genotypes

Alleles



P-value



P-value

Migraine vs Control

0.84

0.66

0.28

0.6

Subtypes



P-value



P-value

MA vs Control

0.99

0.61

0.29

0.59

MO vs Control

0.2

0.91

0.09

0.77

Mig Female vs Control Female

1.85

0.4

0.13

0.72

Mig Male vs Control Male

0.99

0.61

0.18

0.67
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the control group were 66.7%, 47.4% and 22.2%, respectively, results suggesting an association between PFO and
migraine, especially with aura [29].

[10]

CONCLUSIONS
Numerous studies have shown that mutations in the
GATA-4 gene have a significative role in cardiogenesis and
are associated with congenital heart defects, like PFO. A
previous mutation, homozygous deletion 677del C, has been
found on the N-terminal zinc finger of GATA-4 gene, and
previously reported in PFO patients [28].
Our study has reported a lack of association of the S377G
polymorphism in the studied migraine population, which
does not support a correlation between this particular gene
variant and migraine. It appears that the GATA-4 (S377G)
mutation does not play a significant role in common migraine susceptibility. However other variants in this gene
may still play a role in migraine susceptibility. Further studies investigating other GATA-4 variants in families and
case/control populations are warranted to more clearly determine whether this gene plays a role in migraine. Furthermore an association study investigating individuals that present with both PFO and migraine, particularly migraine with
aura, would be very interesting and to this end we are currently collecting subjects with this pertinent information.

[11]
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[15]
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